Navigation Links
Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
Date:9/24/2013

CAMBRIDGE, Mass., Sept. 24, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that FierceBiotech has named Moderna as one of 2013's Fierce 15.

The award designates Moderna as one of the most promising private companies in the biotech industry. Companies from around the world are selected based on strength of technology, venture funding, and their potential to positively impact the treatment of human diseases.

"With its messenger RNA therapies, Moderna has the potential to reinvent the way protein therapies are developed and created," says Executive Editor Ryan McBride. "AstraZeneca validated this potential in a landmark deal that gives Moderna the cash and resources to become a major player in oncology and rare diseases, making this company one to watch closely."

"We are honored to be selected as a Fierce 15 company and recognized for our vision in the field of messenger RNA therapeutics™," said Stephane Bancel, president and founding CEO of Moderna. "This award comes at an exciting time for us, as we recently published our first proof of concept study in Nature Biotechnology, providing important validation of our platform's potential to treat many diseases that cannot be addressed today. We are thrilled to be moving forward quickly and safely to translate our technology into treatment for patients in need."

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alterna
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
2. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... HGS product sales achieved with delivery of ABthrax(TM) to U.S. ... cash balance of $397 million as of March 31, up ... for second Phase 3 trial of Albuferon (R) ... fall 2009 - - Initiation of Syncria (R) ...
... RICHMOND, Calif., April 29 Sangamo BioSciences, Inc. ... success of its zinc finger DNA-binding protein (ZFP) ... Nature by licensing partner Dow AgroSciences ... technology for the efficient generation of maize plants ...
... , ... Austin, Texas (PRWEB) April 29, 2009 -- ... storing and distributing content, today announced the release of CAStor 3.0, ... virtual CAStor nodes in a single, physical server chassis. CAStor Cluster ...
Cached Biology Technology:Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 2Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 3Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 4Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 5Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 6Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 7Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 8Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 9Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 10Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 2Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 3Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 4Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest Baptist ... building for its School of Medicine. Funding for this $50 ... that will be publicly launched next summer. ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... flu viruses that infect birds and humans, a discovery that ... and aid in the development of vaccines against a deadly ... to infect humans depends on whether it can bind to ... respiratory cells. Now that we know what to look ...
... Diego has become the first campus on the West Coast ... voluntary, legally binding trading system to reduce emissions of greenhouse ... the nation to join the climate exchange. Joining the ... conserve energy and reduce greenhouse gases (GHG). Trading in GHG ...
... Ohio State University will battle for the BCS National ... but if the game was held in the Louisiana ... Louisianas wetlands are being lost at the rate of ... against this rapid destruction, the two universities joined forces ...
Cached Biology News:MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3UC San Diego begins trading greenhouse gas credits on Chicago Climate Exchange 2LSU and Ohio State battle on football field, collaborate in research field 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: